🇺🇸 FDA
Patent

US 12173274

Enhanced immune effector cells and use thereof

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 12173274 (Enhanced immune effector cells and use thereof) held by Fate Therapeutics, Inc. expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Fate Therapeutics, Inc.
Grant date
Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K35/545, A61K38/00